Latest news

June 3, 2024

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Read more
May 28, 2024

MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Read more
April 30, 2024

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1…

Read more
April 4, 2024

Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego

Read more
March 7, 2024

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors

Read more
February 6, 2024

Strategikon Closes Series A1 Funding Round to Modernize Clinical Trials Business Operations Worldwide

Read more
February 2, 2024

Challenge pour la Qualité de vie du patient 2024, l’appel à projets est ouvert

Read more
January 29, 2024

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Read more
January 25, 2024

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration

Read more

Stay informed

Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.